Changes in Metabolic Status in Patients With Total Thyroidectomy (Thyroid cancer)

January 30, 2013 updated by: Tel-Aviv Sourasky Medical Center
This study objective is to evaluate the change in mitochondrial uncoupling protein 2 (UCP2) mRNA expression as function of thyroid activity (TSH, T3 and Free T4).

Study Overview

Status

Unknown

Conditions

Detailed Description

Blood will be drown before thyroidectomy, 2 weeks after the operation and 3-4 month after the operation.

Study Type

Observational

Enrollment (Anticipated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Tel Aviv, Israel, 64239
        • Recruiting
        • Tel Aviv Sourasky Medical Center
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients who were diagnosed with thyroid carcinoma and are going throgh total thyroidectomy and recive a thyroid replacement therapy.

Description

Inclusion Criteria:

  • Patients who were diagnosed with thyroid carcinoma and are going to have total thyroidectomy.
  • Patients with unbalanced thyroid hormones.
  • Aged 18-65 years at the time of screening.
  • Provision of written informed consent.

Exclusion Criteria:

  • Patients with Diabetes.
  • Patients with any other chronic inflammatory diseases.
  • Steroid treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in UCP2 mRNA concentrations.
Time Frame: Base line (before opporation), 2 weeks after opporation and for after opporation.
The difference between the result at two weeks and four months compare to base line.
Base line (before opporation), 2 weeks after opporation and for after opporation.

Secondary Outcome Measures

Outcome Measure
Time Frame
Weight
Time Frame: Approximately 4 months
Approximately 4 months
Resting energy expenditure
Time Frame: Approximatly 4 months
Approximatly 4 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2013

Primary Completion (Anticipated)

July 1, 2014

Study Completion (Anticipated)

July 1, 2014

Study Registration Dates

First Submitted

January 27, 2013

First Submitted That Met QC Criteria

January 30, 2013

First Posted (Estimate)

February 1, 2013

Study Record Updates

Last Update Posted (Estimate)

February 1, 2013

Last Update Submitted That Met QC Criteria

January 30, 2013

Last Verified

January 1, 2013

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thyroid Cancer

Subscribe